Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is a clinical-stage biotechnology company focused on regenerative medicine, with its lead program centered on bioengineered human acellular vessels for vascular repair. The company entered the public markets through a merger with Alpha Healthcare Acquisition Corp., a blank-check vehicle sponsored by Alpha Healthcare Holdings LLC that completed its IPO in 2020; the business combination closed in 2021. Humacyte operates in the life sciences and medical technology sector and filed an 8-K with the SEC on June 8, 2023, continuing its regular reporting obligations as a Nasdaq-listed company. To access full filing histories, sponsor profiles, and deal analytics for HUMA and hundreds of other SPAC transactions, sign up for complete data on SpacDesk.